Open Access Open Access  Restricted Access Subscription or Fee Access

Veterinary Therapeutics Based on Liposomes: Recent Advances

Sudha Giri

Abstract


In the veterinary industry, recent breakthroughs in nanomedicine have been investigated and have a wide range of uses. The use of liposomes to deliver medicinal compounds to animals has seen a significant increase in research interest over the last decade. Liposomes are nanosized phospholipid vesicles that can transport a range of substances. Liposomes are an easy-to-make, versatile, and effective delivery technology. They are harmless and biodegradable, with a lengthy in vivo circulation period. This review focuses on recent and ongoing veterinary medical research that may be of interest. This study portrays the current significance and prospects of liposome-based delivery in veterinary medicine by reviewing recent advancements in liposome-based treatments in animal malignancies, vaccinations, and analgesics.


Keywords


Liposome, laboratory animals, Pharmacological, drug bioavailability, veterinary industry

Full Text:

PDF

References


Sadozai, H. and Saeidi, D., 2013. Recent developments in liposome-based veterinary therapeutics. International Scholarly Research Notices, 2013.

Brayden, D.J., Oudot, E.J. and Baird, A.W., 2010. Drug delivery systems in domestic animal species. Comparative and veterinary pharmacology, pp.79-112.

Underwood, C. and Van Eps, A.W., 2012. Nanomedicine and veterinary science: The reality and the practicality. The Veterinary Journal, 193(1), pp.12-23.

Irache, J.M., Esparza, I., Gamazo, C., Agüeros, M. and Espuelas, S., 2011. Nanomedicine: novel approaches in human and veterinary therapeutics. Veterinary parasitology, 180(1-2), pp.47-71.

Torchilin, V.P., 2005. Recent advances with liposomes as pharmaceutical carriers. Nature reviews Drug discovery, 4(2), pp.145-160.

Klibanov, A.L., Maruyama, K., Torchilin, V.P. and Huang, L., 1990. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS letters, 268(1), pp.235-237.

Blume, G. and Cevc, G., 1993. Molecular mechanism of the lipid vesicle longevity in vivo. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1146(2), pp.157-168.

Gabizon, A.A., 2001. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer investigation, 19(4), pp.424-436.

Stealth® Liposomes, Chapter 19 (eds Martin, F. & Lasic, D.) 225–237 (CRC Press, Boca Raton, 1995).

Torchilin, V.P., Omelyanenko, V.G., Papisov, M.I., Bogdanov Jr, A.A., Trubetskoy, V.S., Herron, J.N. and Gentry, C.A., 1994. Poly (ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1195(1), pp.11-20.

Torchilin, V.P. and Trubetskoy, V.S., 1995. Which polymers can make nanoparticulate drug carriers long-circulating? Advanced drug delivery reviews, 16(2-3), pp.141-155.

Allen, T.M. and Hansen, C., 1991. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1068(2), pp.133-141.


Refbacks

  • There are currently no refbacks.